The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis

Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P(1)) and 5 (S1P(5)) modulator approved in the United States and the European Union as an oral treatment for adults with relapsing forms of multiple sclerosis (RMS), including active secondary progressive multiple sclerosis (SPMS...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohan, Stanley L., Benedict, Ralph H. B., Cree, Bruce A. C., DeLuca, John, Hua, Le H., Chun, Jerold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259525/
https://www.ncbi.nlm.nih.gov/pubmed/35725892
http://dx.doi.org/10.1007/s40263-022-00927-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259525/
https://www.ncbi.nlm.nih.gov/pubmed/35725892
http://dx.doi.org/10.1007/s40263-022-00927-z

Ejemplares similares